Results 191 to 200 of about 21,695 (218)

Coronary drug-coated balloons: Current evidence and emerging trends. [PDF]

World J Cardiol
Bhandari M, Pradhan A, Behera S, Singh AK.   +3 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Drug-eluting balloon for instent restenosis

Heart, 2013
To the Editor We read with interest the meta-analysis by Indermuehle A et al 1 which reported that drug-eluting balloon (DEB) appears to show great promise for instent restenosis (ISR), and could reduce the risk for major adverse cardiac events compared with plain balloon angioplasty (BA) or implantation of drug-eluting stent (DES) in the treatment of ...
Yin, Chen, Shilian, Hu, Lei, Wu
openaire   +3 more sources

Drug Eluting Balloons

Techniques in Vascular and Interventional Radiology, 2010
Ever since the first percutaneous transluminal angioplasty (PTA) was carried out in Switzerland in 1977, restenosis remains a major drawback of this minimally invasive treatment intervention. Numerous attempts to increase vessel patency after PTA have included systemic medications and endovascular brachytherapy, but these techniques have not met our ...
Nicolas A, Diehm, Hanno, Hoppe, Dai-Do, Do   +2 more
openaire   +2 more sources

Drug-eluting balloon: new tool in the box

Expert Review of Medical Devices, 2010
Percutaneous coronary intervention has revolutionized coronary revascularization therapy. It is increasingly becoming an attractive alternative to medical therapy and surgical revascularization in the treatment of coronary artery disease. Restenosis is a major challenge, and has been described as the Achilles heel of the procedure.
Sumeet, Sharma, Neville, Kukreja, Christos, Christopoulos, Diana A, Gorog   +3 more
openaire   +2 more sources

Outcomes of drug eluting stents vs. drug eluting balloons. A single center experience

European Heart Journal, 2023
Abstract Introduction Drug eluting stents (DES) are considered the default treatment option in the current era of percutaneous coronary interventions (PCI). Nevertheless, the use of drug eluting balloons (DEB) remains highly relevant, especially in the setting of in stent restenosis (ISR), and de-novo
M Kheifets, O Rahat, T Bental, A Levi, A Samara, G Greenberg, P Codner, G Witberg, H Vaknin-Assa, R Kornowski, L Perl   +10 more
openaire   +1 more source

Drug-eluting balloon: design, technology and clinical aspects

Biomedical Materials, 2018
A drug-eluting balloon is a non-stent technology in which the effective homogenous delivery of anti-proliferative drugs is processed by the vessel wall through an inflated balloon. This is done to restore luminal vascularity in order to treat atherosclerosis, in-stent restenosis and reduce the risk of late thrombosis without implanting a permanent ...
Meenasree Bukka, Poorna Jyothi Rednam, Mukty Sinha   +2 more
openaire   +2 more sources

A journey from CABG to drug‐eluting balloon

Catheterization and Cardiovascular Interventions, 2013
A middle aged male underwent series of percutaneous coronary intervention (PCI) of left main stenosis for Canadian cardiovascular society (CCS) IV angina. He developed recurrent severe proliferative in‐stent restenosis which was treated with different available options including drug‐eluting stents and finally with drug‐eluting balloons.
Sajid, Dhakam, Nasir, Rahman
openaire   +2 more sources

Drug-eluting balloons versus drug-eluting stents for small vessel coronary artery disease: a meta-analysis

Coronary Artery Disease, 2020
Objective We aimed to conduct a network meta-analysis of treatments for small vessels coronary artery disease between drug-eluting balloon (DEB) and drug-eluting stent (DES). Method A meta-analysis comparing DEB and DES outcomes was performed using the Medline, Embase, and Cochrane ...
Song, Cai-Xia, Zhou, Chao, Hou, Wenbo, Yin, Yuxia, Lu, Shoutao, Liu, Guang, Duan, Cuihai, Li, Maoquan, Zhang, Haijun   +8 more
openaire   +3 more sources